Troglitazone-induced hepatic failure leading to liver transplantation. A case report

Annals of Internal Medicine

Volumn 129, Issue 1, 1998, Pages 38-41

  Neuschwander Tetri, Brent A ^a,b   Isley, William L ^c   Oki, Julie C ^c   Ramrakhiani, Sanjay ^b   Quiason, Stella G ^c   Phillips, Nancy J ^b   Brunt, Elizabeth M ^b  

^a SAINT LOUIS UNIVERSITY   (United States)

^b SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF MISSOURI KANSAS CITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INSULIN; TROGLITAZONE;

ADULT; ARTICLE; CASE REPORT; CLINICAL EXAMINATION; DRUG WITHDRAWAL; FEMALE; FOOD AND DRUG ADMINISTRATION; HISTOPATHOLOGY; HUMAN; LIVER FAILURE; LIVER TRANSPLANTATION; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL;

EID: 0032125137     PISSN: 00034819     EISSN: None     Source Type: Journal    
DOI: 10.7326/0003-4819-129-1-199807010-00009     Document Type: Article

References (10)

1. Kumar S, Boulton AJ, Beck-Nielsen H, Berthezene F, Muggeo M, Persson B, et al. Troglitazone, an insulin action enhancer, improves metabolic control in NIDDM patients. Troglitazone Study Group. Diabetologia. 1996;39: 701-9.
2. Spencer CM, Markham A. Troglitazone. Drugs. 1997;54:89-101.
3. Lehmann JM, Moore LB, Smith-Oliver TA, Wilkison WO, Willson TM, Kliewer SA. An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma). J Biol Chem. 1995;270:12353-6.
4. Henry RR. Thiazolidinediones. Endocrin Metab Clin North Am. 1997;26:553-73.
5. Watkins PB, Whitcomb RW. Hepatic dysfunction associated with troglitazone [Letter]. N Engl J Med. 1998;338:916-7.
6. Misbin RI. Review of liver toxicity of troglitazone. Meeting of the Food and Drug Administration Cardiorenal Advisory Committee, 21 January 1998. Bethesda, MD.
7. Prescribing information for Rezulin. Parke-Davis, Morris Plains, NJ. December 1997.
8. Imura H. A novel antidiabetic drug, troglitazone - reason for hope and concern [Editorial]. N Engl J Med. 1998;338:908-9.
9. Cominacini L, Garbin U, Pastorino AM, Campagnola M, Fratta Pasini A, Davoli A, et al. Effects of troglitazone on in vitro oxidation of LDL and HDL induced by copper ions and endothelial cells. Diabetologia. 1997;40:165-72.
10. Inoue I, Katayama S, Takahashi K, Negishi K, Miyazaki T, Sonoda M, et al. Troglitazone has a scavenging effect on reactive oxygen species. Biochem Biophys Res Comm. 1997;235:113-6.